GR3031479T3 - Drug system. - Google Patents

Drug system.

Info

Publication number
GR3031479T3
GR3031479T3 GR990402571T GR990402571T GR3031479T3 GR 3031479 T3 GR3031479 T3 GR 3031479T3 GR 990402571 T GR990402571 T GR 990402571T GR 990402571 T GR990402571 T GR 990402571T GR 3031479 T3 GR3031479 T3 GR 3031479T3
Authority
GR
Greece
Prior art keywords
polysaccharide
drug
matrix
drug system
natural macromolecule
Prior art date
Application number
GR990402571T
Other languages
Greek (el)
English (en)
Inventor
Margaret Joan Taylor
Original Assignee
Univ Montfort
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montfort filed Critical Univ Montfort
Publication of GR3031479T3 publication Critical patent/GR3031479T3/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
GR990402571T 1992-01-10 1999-10-08 Drug system. GR3031479T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929200638A GB9200638D0 (en) 1992-01-10 1992-01-10 Drug system
PCT/GB1993/000034 WO1993013803A1 (en) 1992-01-10 1993-01-08 Drug system

Publications (1)

Publication Number Publication Date
GR3031479T3 true GR3031479T3 (en) 2000-01-31

Family

ID=10708507

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990402571T GR3031479T3 (en) 1992-01-10 1999-10-08 Drug system.

Country Status (11)

Country Link
US (2) US5830506A (de)
EP (1) EP0626862B1 (de)
JP (1) JP4025363B2 (de)
AT (1) ATE183927T1 (de)
AU (1) AU3263093A (de)
DE (1) DE69326234T2 (de)
DK (1) DK0626862T3 (de)
ES (1) ES2135458T3 (de)
GB (1) GB9200638D0 (de)
GR (1) GR3031479T3 (de)
WO (1) WO1993013803A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200638D0 (en) * 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii
GB9805896D0 (en) 1998-03-20 1998-05-13 Eglise David Remote analysis system
WO2001016575A1 (en) * 1999-08-27 2001-03-08 M-Biotech, Inc. Glucose biosensor
WO2001081890A2 (en) * 2000-04-22 2001-11-01 M-Biotech, Inc. Hydrogel biosensor and biosensor-based health alarm system
GB0116860D0 (en) * 2001-07-10 2001-09-05 Univ Montfort Gel compositions
WO2003015704A2 (en) 2001-08-17 2003-02-27 University Of Pittsburgh Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders
US6943267B1 (en) 2001-08-24 2005-09-13 Utah State University Thiophosphonate inhibitors of phosphatase enzymes and metallophosphatases
US20080279936A1 (en) * 2001-10-10 2008-11-13 The University Of Pittsburgh Estradiol metabolites for reduction of endothelin production
US20090118605A1 (en) * 2002-08-30 2009-05-07 Northwestern University Surface-enhanced raman nanobiosensor
WO2004056311A2 (en) 2002-12-17 2004-07-08 Massachusetts Institute Of Technology Stimuli-responsive systems for controlled drug delivery
US20060194775A1 (en) * 2003-02-20 2006-08-31 University Of Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
WO2004073643A2 (en) * 2003-02-20 2004-09-02 University Of Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
US7806856B2 (en) * 2005-04-22 2010-10-05 Accessclosure, Inc. Apparatus and method for temporary hemostasis
WO2007047997A2 (en) * 2005-10-19 2007-04-26 Smartcells, Inc. Methods for reducing the mitogenicity of lectin compositions
ES2791683T3 (es) 2009-01-28 2020-11-05 Smartcells Inc Sistemas a base de conjugados para la administración controlada de fármacos
EP2391217A4 (de) 2009-01-28 2015-05-20 Smartcells Inc Synthetische konjugate und ihre verwendung
US8906850B2 (en) 2009-01-28 2014-12-09 Smartcells, Inc. Crystalline insulin-conjugates
US8846103B2 (en) 2009-01-28 2014-09-30 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2805902A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
EP2598527A4 (de) 2010-07-28 2014-01-08 Smartcells Inc Rekombinant exprimierte insulinpolypeptide und anwendungen davon
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
GB201314640D0 (en) 2013-08-15 2013-10-02 Univ Montfort Matrix gel
AU2014329567B2 (en) 2013-10-04 2019-07-25 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US11041009B2 (en) 2017-03-23 2021-06-22 Merck Sharp & Dohme Corp. Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
CN114432243B (zh) * 2022-01-20 2023-08-29 华南师范大学 一种响应pH和葡萄糖的纳米载体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348387A (en) * 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
US6159502A (en) * 1991-04-02 2000-12-12 Biotech Australia Pty Ltd Oral delivery systems for microparticles
GB9200638D0 (en) 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
GB9313484D0 (en) * 1993-06-30 1993-08-11 Univ Montfort Drug system ii

Also Published As

Publication number Publication date
EP0626862A1 (de) 1994-12-07
ATE183927T1 (de) 1999-09-15
US5830506A (en) 1998-11-03
DK0626862T3 (da) 1999-12-13
US7063863B2 (en) 2006-06-20
WO1993013803A1 (en) 1993-07-22
DE69326234T2 (de) 1999-12-30
US20020168409A1 (en) 2002-11-14
JPH07507268A (ja) 1995-08-10
GB9200638D0 (en) 1992-03-11
EP0626862B1 (de) 1999-09-01
AU3263093A (en) 1993-08-03
ES2135458T3 (es) 1999-11-01
JP4025363B2 (ja) 2007-12-19
DE69326234D1 (de) 1999-10-07

Similar Documents

Publication Publication Date Title
GB9200638D0 (en) Drug system
AU628674B2 (en) Polymer complexes of a sugar response type
Draget et al. Alginate based new materials
US4189370A (en) Process for obtaining gels of N-methylol-acrylamide copolymers and application of said gels for the stepped gradient separation of seric lipoproteins
CN108676178B (zh) 改性多糖水凝胶的制备方法及制备的改性多糖水凝胶
Rousseau et al. Entrapment and release of sodium polystyrene sulfonate (SPS) from calcium alginate gel beads
DE2426988C2 (de) Verfahren zur Trägerbindung biologisch aktiver Proteine
US5902607A (en) Reversible cross-linked gel
US5089272A (en) Process for producing capsules having a permeability-controllable membrane
GB1463301A (en) Polymer properties
ES8206984A1 (es) Procedimiento de separacion de mezclas biologicas
AU3877200A (en) Hydrogel-forming system with hydrophobic and hydrophilic components
GB1283857A (en) Size for glass fibres
YU46797B (sh) Postupak za dobijanje ojačanog poliuretanskog polimera
CA2112450A1 (en) Cross-linked linear polysaccharide polymers as gels for electrophoresis
Liao et al. Temperature/pH dual sensitive Hericium erinaceus residue carboxymethyl chitin/poly (N-isopropyl acrylamide) sequential IPN hydrogels
CS13891A2 (en) Refractory glass and method of its production
DE3167132D1 (en) Gel based on water-soluble poly(meth)acrylic acid derivatives, process for its preparation and its use
EP0401044A3 (de) Absorbierende Polymere und ihre Herstellung
NO940112L (no) Fremgangsmaate for fremstilling av en dispersjon og for fremstilling av polymerpartikler
NO131417B (de)
He et al. In Vitro Synthesis of Branchless Linear (1→ 6)-α-d-Glucan by Glucosyltransferase K: Mechanical and Swelling Properties of Its Hydrogels Crosslinked with Diglycidyl Ethers
EA199900918A2 (ru) Способ получения монодисперсных гелеобразных катионитов
De Moor et al. Long-term structural changes in pH-sensitive hydrogels
US5215752A (en) Pharmaceutical tablets and capsule granulates of scleroglucan and active substance